Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: December-19-14
Credit Expiration Date: December-19-15

Faculty

James F. Donohue, MD
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC

Credit Hours

0.75 AMA PRA Category 1 Credit

Medium

Mobile + Online on QuantiaMD

Program Description

Approximately 25 million Americans (8% of the population) suffer from asthma. Due to a variety of barriers, patients with asthma often do not have their asthma well controlled, leading to suboptimal patient outcomes. The CDC reports an estimated 13.9 million people with asthma experienced an asthma attack in the previous 12 months, a measure indicating suboptimal asthma control. With suboptimal asthma control, many patients suffer from asthma symptoms as well as asthma-related events that could be prevented, such as missed school or workdays, emergency department visits, hospitalizations, and death. The aim of this activity is to instruct primary care physicians on strategies to improve the management of asthma, ultimately resulting in better patient outcomes.

Program Developer/Facilitator


.

Target Audience

This educational activity is designed to meet the needs of primary care physicians and other clinicians involved in the care of patients with asthma.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Develop safe and effective individualized treatment plans to help patients achieve asthma control.
  2. Provide asthma self-management education to prepare patients to become active partners in achieving asthma control.
  3. Describe recent developments in clinical research to improve treatment options available for asthma.

Disclosures

It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity.

Dr. Donohue has reported relationships with the following commercial interests:
Consultant/Advisor: Amiral, Astra Zeneca, Boehringer Ingelheim, Forest, GlaxoSmith Kline, Novartis, Pfizer
Advisory Board: Mylan, Novartis, Pfizer
DSMB: Pearl, Otsuka, Teva

Perelman School of Medicine at the University of Pennsylvania Office of CME:
Zalman S. Agus, MD, has reported that he has no relevant financial relationships.
Mila Kostic has reported that she has no relevant financial relationships.
Michael Schoen, PhD, has reported that he has no relevant financial relationships.

MCM Education:
Gena Dolson has reported that she has no relevant financial relationships


Investigational and/or Off-Label Use of Commercial Products and Devices: The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

In this educational activity, the faculty reports his presentation will contain reference to investigational and/or off-label uses of agents, including fluticasone fumarate/vilanterol, tiotropium, macrolides, reslizumab, dupilumab, and mepolizumab.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Perelman School of Medicine at the University of Pennsylvania and MCM Education. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.

The Perelman School of Medicine at the University of Pennsylvania designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release date: December 19, 2014
Last review date: December 19, 2014
Expiration date: December 19, 2015

Commercial Support Statements

Supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Instructions

Completion Instructions

  1. Accessing Activity:
    * Link to and Log into program on QuantiaMD.com
    * Take the pre-test
    * Review the activity
    * Take the post-test and score 75%
    * You are allowed a total of 3 attempts
    * Complete the evaluation
    * View, print, or save a CME certificate verifying your
    credit/participation in this activity
  2. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee

$0.00

There is no charge for CME credit.

Disclaimer

© 2014, MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the Perelman School of Medicine at the University of Pennsylvania, or Novartis Pharmaceuticals Corporation. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS